SecBot SecBot
6-K ·Filed Apr 7, 2026

ASND

Ascendis Pharma A/S
BULLISH
Impact 8/10
Horizonmonths Processed7mo ago SEC0001193125-26-144463
Notable filing: 6-K
Actionable Insight ▲ Bullish

Traders should consider this a positive catalyst given the combination of commercial launch and 7-year market exclusivity in a high-unmet-need pediatric population. The exclusivity reduces near-term competitive risk and supports premium pricing and reimbursement. Monitor sales ramp in upcoming quarters as a key indicator of uptake.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$220.48
T+0 close · Apr 7, 2026 · via day close
Latest settled
+24.50%
T+60 · $274.50
Vs SPY
+11.23%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 7 $220.48entry
  2. T+1 · 7mo ago +5.77%α +3.23% · $233.20
  3. T+5 · 7mo ago +13.32%α +7.99% · $249.84
  4. T+20 · 7mo ago +3.73%α −6.05% · $228.71
  5. T+60 · 5mo ago +24.50%α +11.23% · $274.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Ascendis Pharma announced that YUVIWEL (navepegritide), its once-weekly treatment for children with achondroplasia, has been granted orphan drug exclusivity by the FDA and is now commercially available in the United States. The exclusivity extends through February 27, 2033, providing market protection for this first-in-class therapy.

Key Facts

  • YUVIWEL (navepegritide) received orphan drug exclusivity from the FDA
  • YUVIWEL is now commercially available in the U.S.
  • It is the first and only once-weekly treatment approved to increase linear growth in children 2 years and older with achondroplasia
  • Orphan drug exclusivity runs through February 27, 2033
  • The drug provides continuous systemic exposure to CNP over the weekly dosing interval

Financial Impact

Significant long-term revenue potential due to market exclusivity and first-mover advantage in a rare disease indication

revenuemarket sharevaluation

Risk Factors

  • Market acceptance and reimbursement challenges
  • Dependence on third-party manufacturers and supply chain
  • Potential safety or efficacy findings post-launch

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001193125-26-144463
Document: 0001193125-26-144463-index-headers.html0001193125-26-144463
Document: 0001193125-26-144463-index.html0001193125-26-144463
Document: 0001193125-26-144463.txt0001193125-26-144463

Track record

41 reports on ASND

Performance horizon

13 of 18 bullish or bearish reports moved the stock their way by T+60. Best: +26.62% at T+20 after the Jun 2, 2026 report. 24 of 26 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $271.96 Now $271.73 −0.08% settles Feb 12
  2. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $275.39 Now $271.73 −1.33% settles Feb 11
  3. Nov 12, 20264d ago 6-K Bullish 6/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  4. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $267.07 Now $271.73 +1.74% settles Feb 10
  5. Nov 6, 202610d ago 6-K Bullish 6/10 Entry $259.85 Now $271.73 +4.57% settles Feb 5
  6. Nov 6, 202610d ago Press Release Bullish 6/10 Entry $256.82 Now $271.73 +5.81% settles Feb 4
  7. Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $253.45 Now $271.73 +7.21% settles Feb 3
  8. Nov 2, 202614d ago Institutional Cluster Bullish 4/10 Entry $250.17 Now $271.73 +8.62% settles Feb 1
  9. Oct 26, 202621d ago 6-K Bullish 5/10 Entry $245.85 Now $271.73 +10.53% settles Jan 25
  10. Oct 16, 20264w ago 6-K Bullish 7/10 Entry $225.25 Now $271.73 +20.63% settles Jan 13
Showing 10 of 41

US Market Status

Market Closed · Opens Wed (11h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 7, 2026